Table 1.

Table of characteristics of the selected studies for the meta-analysis.

References	Study design	Intervention drug	Mode of administration	Dose	Sample size	Age: mean (SD)	Indication for treatment	Outcome studied
Riva-Posse et al. (26)	Retrospective analysis of clinical use	Ketamine	Intravenous	0.5 mg/kg	684	56.69 (12.86)	TRD	SBP DBP
Grunebaum et al. (27)	RCT, midazolam controlled, parallel	Ketamine	Intravenous	0.5 mg/kg	74	38.4 (13.2)	TRD	SBP DBP
Taylor et al. (14)	RCT, saline controlled, crossover	Ketamine	Intravenous	0.5 mg/kg	18	30.78 (13.50)	SAD	SBP DBP HR
Su et al. (28)	RCT, saline controlled, parallel	Ketamine	Intravenous	0.2, 0.5 mg/kg	47	46.75 (11.65)	TRD	SBP DBP HR
George et al. (29)	RCT, midazolam-controlled, multiple-crossover	Ketamine	Subcutaneous	0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg	9	65.6 (5.7)	TRD	HR
Grunebaum et al. (27)	RCT, midazolam-controlled, parallel	Ketamine	Intravenous	0.5 mg/kg	15	39 (10.2)	TRD	SBP DBP
Vande Voort et al. (30)	Open-label trial	Ketamine	Intravenous	0.5 mg/kg	12	45.8 (8.0)	TRD	SBP DBP
Lapidus et.al. (31)	RCT, saline-controlled, crossover	Ketamine	Intranasal	50 mg	18	48.0 (12.8)	TRD	SBP DBP HR
Murrough et al. (21)	RCT, midazolam-controlled, parallel	Ketamine	Intravenous	0.5 mg/kg	47	46.9 (12.8)	TRD	SBP DBP
Bloch et al. (25)	Open-label trial	Ketamine	Intravenous	0.5 mg/kg	4	34.2 (9.0)	OCD	SBP DBP HR
Krystal et al. (32)	RCT, saline-controlled, crossover	Ketamine	Intravenous	0.1, 0.5 mg/kg	19	23.7 (0.9)	TRD	HR
Fedgchin et al. (33)	RCT, saline-controlled, parallel	Esketamine	Intranasal	56, 84 mg	116	46.05 (11.14)	TRD	SBP DBP
Daly et al. (34)	RCT, saline-controlled, parallel	Esketamine	Intranasal	56–84 mg	346	44.9 (12.58)	TRD	SBP DBP
Ochs-Ross et al. (35)	RCT, saline-controlled, parallel	Esketamine	Intranasal	28–84 mg	72	70.6 (4.79)	TRD	SBP DBP
Wajs et al. (36)	Open-label study	Esketamine	Intranasal	28–84 mg	771	52.2 (13.69)	TRD	SBP DBP